Vycor Medical FY26 Q2 net loss narrows to $2,180; revenue falls 16% to $418,264
VYCO•Quarterly results
Vycor Medical posted revenue of USD 418,264 for the quarter ended June 30, 2026, down 16% year over year.
Net loss narrowed to USD 2,180 for the six months ended June 30, 2026 from USD 14,676 a year earlier.
Gross profit fell 17% to USD 344,445, with gross margin easing 2 percentage points to 82%.
Segment performance and balance sheet
Vycor Medical segment revenue slid 17% to USD 401,224 on lower international sales; NovaVision revenue rose 17% to USD 17,040.
Cash rose to USD 158,907 at June 30, 2026 from USD 86,982 at Dec. 31, 2025; working capital deficit widened to USD 4.29 million.
